Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)

OBJECTIVES:To assess for the first time the safety and pharmacokinetics of an antiprogrammed cell death-ligand 1 immune checkpoint inhibitor (BMS-936559; Bristol-Myers Squibb, Princeton, NJ) and its effect on immune biomarkers in participants with sepsis-associated immunosuppression. DESIGN:Randomiz...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Critical care medicine 2019-05, Vol.47 (5), p.632-642
Hauptverfasser:	Hotchkiss, Richard S., Colston, Elizabeth, Yende, Sachin, Angus, Derek C., Moldawer, Lyle L., Crouser, Elliott D., Martin, Greg S., Coopersmith, Craig M., Brakenridge, Scott, Mayr, Florian B., Park, Pauline K., Ye, June, Catlett, Ian M., Girgis, Ihab G., Grasela, Dennis M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Cytokines Dose-Response Relationship, Drug Female Humans Immunologic Factors Male Middle Aged Programmed Cell Death 1 Receptor - metabolism Sepsis - drug therapy Sepsis - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!